Decreased neointimal extracellular matrix formation in RAGE-knockout mice after microvascular denudation

CardioVascular and Interventional Radiology

Volumn 35, Issue 6, 2012, Pages 1439-1447

  Grözinger, Gerd ^a   Schmehl, Jörg ^a   Bantleon, Rüdiger ^a   Kehlbach, Rainer ^a   Mehra, Tarun ^a   Claussen, Claus ^a   Wiesinger, Benjamin ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Animal experiments; Arterial intervention; Endovascular treatment; Experimental IR; Peripheral vascular; Stenosis Restenosis

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA ACTIN; CELL NUCLEUS ANTIGEN; COLLAGEN; SCLEROPROTEIN; VON WILLEBRAND FACTOR; ACTIN; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; CYCLINE; IMMUNOGLOBULIN RECEPTOR; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DISEASE ACTIVITY; EXTRACELLULAR MATRIX; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MORPHOMETRICS; MOUSE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RESTENOSIS; SMOOTH MUSCLE FIBER; SPECIES COMPARISON; WILD TYPE; ANIMAL; FEMORAL ARTERY; METABOLISM; MOUSE MUTANT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACTINS; ANIMALS; COLLAGEN; EXTRACELLULAR MATRIX; FEMORAL ARTERY; MICE; MICE, KNOCKOUT; NEOINTIMA; PROLIFERATING CELL NUCLEAR ANTIGEN; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VON WILLEBRAND FACTOR;

EID: 84878051534     PISSN: 01741551     EISSN: 1432086X     Source Type: Journal    
DOI: 10.1007/s00270-011-0319-3     Document Type: Article

References (37)

1. Schleicher E, Friess U (2007) Oxidative stress, AGE, and atherosclerosis. Kidney Int 2007 106(1):S17-S26
2. Duda SH, Bosiers M, Lammer J et al (2006) Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther 13(6):701-710
3. Ritthaler U, Deng Y, Zhang Y et al (1995) Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. Am J Pathol 146(3):688-694
4. Sakaguchi T, Yan SF, Yan SD et al (2003) Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 111(7):959-972
5. Yamagishi S, Matsui T, Nakamura K (2007) Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr Drug Targets 8(10):1138-1143
6. Ihara Y, Egashira K, Nakano K et al (2007) Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis. J Mol Cell Cardiol 43(4):455-464
7. Wang L, Li S, Jungalwala FB (2008) Receptor for advanced glycation end products (RAGE) mediates neuronal differentiation and neurite outgrowth. J Neurosci Res 86(6):1254-1266
8. Tesarova P, Kalousova M, Jachymova M et al (2007) Receptor for advanced glycation end products (RAGE)-soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Cancer Invest 25(8):720-725
9. Constien R, Forde A, Liliensiek B et al (2001) Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line. Genesis 30(1):36-44
10. Feuls R, Chereshnev I, Bantleon R et al (2003) Microvascular denudation of the femoral artery of the mouse as a model for restenosis. Rofo 175(7):952-957
11. Kobayashi M, Inoue K, Warabi E et al (2005) A simple method of isolating mouse aortic endothelial cells. J Atheroscler Thromb 12(3):138-142
12. Jansson G (1991) Oestrogen-induced enhancement of myeloperoxidase activity in human polymorphonuclear leukocytes - a possible cause of oxidative stress in inflammatory cells. Free Radic Res Commun 14(3):195-208
13. Miyata T, Ishikawa S, Asahi K et al (1999) 2-Isopropylidenehydrazono-4- oxo-thiazolidin-5-ylacetanilide (OPB-9195) treatment inhibits the development of intimal thickening after balloon injury of rat carotid artery: role of glycoxidation and lipoxidation reactions in vascular tissue damage. FEBS Lett 445(1):202-206
14. Anderson MM, Requena JR, Crowley JR et al (1999) The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 104(1):103-113
15. Li J, Qu X, Schmidt AM (1998) Sp1-binding elements in the promoter of RAGE are essential for amphoterin-mediated gene expression in cultured neuroblastoma cells. J Biol Chem 273(47):30870-30878
16. Li J, Schmidt AM (1997) Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 272(26):16498-16506
17. Scaffidi P, Misteli T, Bianchi ME (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418(6894):191-195
18. Schmidt AM, Stern D (2000) Atherosclerosis and diabetes: the RAGE connection. Curr Atheroscler Rep 2(5):430-436
19. Lander HM, Tauras JM, Ogiste JS et al (1997) Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 272(28):17810-17814
20. Bierhaus A, Schiekofer S, Schwaninger M et al (2001) Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 50(12):2792-2808
21. Bierhaus A, Nawroth PP (2009) Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 52(11):2251-2263
22. Oldfield MD, Bach LA, Forbes JM et al (2001) Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 108(12):1853-1863
23. Throckmorton DC, Brogden AP, Min B et al (1995) PDGF and TGF-beta mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int 48(1):111-117
24. Farb A, Kolodgie FD, Hwang JY et al (2004) Extracellular matrix changes in stented human coronary arteries. Circulation 110(8):940-947
25. Ikonomidis JS, Jones JA, Barbour JR et al (2007) Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with bicuspid or tricuspid aortic valves. J Thorac Cardiovasc Surg 133(4):1028-1036
26. Baker AH, Edwards DR, Murphy G (2002) Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115(Pt 19):3719-3727
27. Hofmann Bowman M, Wilk J, Heydemann A et al (2010) S100A12 mediates aortic wall remodeling and aortic aneurysm. Circ Res 106(1):145-154
28. Kamioka M, Ishibashi T, Ohkawara H et al (2011) Involvement of membrane type 1-matrix metalloproteinase (MT1-MMP) in RAGE activation signaling pathways. J Cell Physiol 226(6):1554-1563
29. Schober W, Wiskirchen J, Kehlbach R et al (2002) Antiproliferative effects of the antiallergic agent azelastine on human aortic smooth-muscle cells: an in vitro study. Invest Radiol 37(5):248-253
30. Kubota Y, Kichikawa K, Uchida H et al (1995) Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. An experimental study. Invest Radiol 30(9):532-537
31. Tepe G, Brehme U, Seeger H et al (2002) Endothelin A receptor antagonist LU 135252 inhibits hypercholesterolemia-induced, but not deendothelialization- induced, atherosclerosis in rabbit arteries. Invest Radiol 37(6):349-355
32. Watson AM, Soro-Paavonen A, Sheehy K et al (2011) Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia 54:681-689
33. Yamagishi S, Nakamura K, Matsui T et al (2008) Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opin Invest Drugs 17(7):983-996
34. Takagi T, Yamamuro A, Tamita K et al (2003) Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 146(2):E5
35. Choi D, Kim SK, Choi SH et al (2004) Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 27(11):2654-2660
36. Barile GR, Schmidt AM (2007) RAGE and its ligands in retinal disease. Curr Mol Med 7(8):758-765
37. van Zoelen MA, Yang H, Florquin S et al (2009) Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock 31(3):280-284